Cargando…
Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer
INTRODUCTION: Clinical research is conducted by academia, cooperative groups (CGs) or pharmaceutical industry. Here, we evaluate the role of CGs and funding sources in the development of guidelines for breast cancer therapies. RESULTS: We identified 94 studies. CGs were involved in 28 (30%) studies...
Autores principales: | Tibau, Ariadna, Anguera, Geòrgia, Andrés-Pretel, Fernando, Templeton, Arnoud J., Seruga, Bostjan, Barnadas, Agustí, Amir, Eitan, Ocana, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871097/ https://www.ncbi.nlm.nih.gov/pubmed/29599926 http://dx.doi.org/10.18632/oncotarget.24589 |
Ejemplares similares
-
Clinical benefit of cancer drugs approved in Switzerland 2010–2019
por: Adam, Roman, et al.
Publicado: (2022) -
Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
por: Al-Mubarak, Mustafa, et al.
Publicado: (2014) -
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression
por: Templeton, Arnoud J., et al.
Publicado: (2016) -
Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade
por: Ribnikar, Domen, et al.
Publicado: (2021) -
Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
por: Saleh, Ramy R., et al.
Publicado: (2020)